Diffusion Pharmaceuticals Regains Compliance with Nasdaq Capital Market Minimum Equity Rule
20 nov. 2017 08h00 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq:DFFN) (“Diffusion” or “the Company”), is a clinical-stage biotechnology company focused on extending...
Diffusion Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
13 nov. 2017 08h00 HE
|
Diffusion Pharmaceuticals Inc.
FDA Clears Phase 3 Protocol for Patient Enrollment in GBM Brain Cancer Trial“First Patient In” Expected this YearCompany Charter Amendment Addresses Nasdaq Listing IssueAdditions to Board and...
Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme
17 oct. 2017 07h30 HE
|
Diffusion Pharmaceuticals Inc.
CHARLOTTESVILLE, Va., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on extending the...
Diffusion Pharmaceuticals to Present at the 2017 BIO Investor Forum
10 oct. 2017 10h00 HE
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...
Diffusion Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
05 sept. 2017 11h10 HE
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the...
Diffusion Pharmaceuticals Names William Hornung Chief Business Officer
23 août 2017 07h30 HE
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...
Diffusion Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
14 août 2017 16h01 HE
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) (“Diffusion” or “the Company”), a clinical-stage biotechnology company focused on the development...
Diffusion Pharmaceuticals Selects Contract Research Organization for Phase 3 Clinical Trial of Lead Compound TSC for Inoperable GBM Brain Cancer
31 juil. 2017 08h30 HE
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., July 31, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer...
Diffusion Pharmaceuticals Achieves Drug Production Milestone For Planned Phase 3 Clinical Trial In Inoperable GBM Brain Cancer
20 juil. 2017 08h30 HE
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., July 20, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company developing novel small molecule therapeutics for cancer...
Diffusion Pharmaceuticals Appoints Dr. Robert Ruffolo to Board of Directors
06 juil. 2017 08h00 HE
|
Diffusion Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., July 06, 2017 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule...